Related Experiment Video
Updated: May 19, 2026

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
Published on: April 28, 2015
Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug
Lucie Yang1, Ira Krefting, Alex Gorovets
1Office of New Drugs, United States Food and Drug Administration, 10903 New Hampshire Ave, Building 22, Room 2335, Silver Spring, MD 20993, USA. Lucie.Yang@fda.hhs.gov
Abstract:
In 2007, the Food and Drug Administration requested that manufacturers of all approved gadolinium-based contrast agents (GBCAs), drugs widely used in magnetic resonance imaging, use nearly identical text in their product labeling to describe the risk of nephrogenic systemic fibrosis (NSF). Accumulating information about NSF risks led to revision of the labeling text for all of these drugs in 2010. The present report summarizes the basis and purpose of this class-labeling approach and describes some of the related challenges, given the evolutionary nature of the NSF risk evidence. The class-labeling approach for presentation of product risk is designed to decrease the occurrence of NSF and to enhance the safe use of GBCAs in radiologic practice.
Related Concept Videos
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies III: Computed Tomography
Radiological Investigation I: X-ray and CT
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Nephrotic Syndrome I : Introduction
Imaging Studies VII: Vascular Imaging

